Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhea-AI Summary
Heron Therapeutics (Nasdaq: HRTX) will report fourth quarter and full year 2025 results on Thursday, February 26, 2026 with a conference call and live webcast at 8:30 a.m. ET.
According to the company, the call will review financial results and recent business highlights; a replay will be available on Heron’s investor website for 60 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
HRTX was flat while peers showed mixed moves: EPRX up 3.44%, SLS and TRDA modestly higher, MDWD and NTHI lower. This points to stock-specific factors rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Prelim 2025 revenue | Positive | +9.4% | Preliminary Q4 and full-year 2025 net revenue highlighted portfolio growth. |
| Dec 04 | Guideline inclusion | Positive | +2.4% | APONVIE added to PONV guidelines, reinforcing its clinical and commercial positioning. |
| Nov 04 | Q3 2025 earnings | Positive | -3.4% | Q3 2025 results with revenue growth and reaffirmed guidance and EBITDA outlook. |
| Oct 29 | Board appointment | Neutral | -2.6% | Appointment of Thomas Cusack to the board under a cooperation agreement. |
| Oct 21 | Earnings date | Neutral | -8.5% | Announcement of Q3 2025 earnings date and investor conference call details. |
Commercial and product-related positives have often seen supportive price reactions, but at least one earnings release with reaffirmed guidance drew a negative move, showing occasional divergence on fundamentals.
Over the past few months, Heron moved from a Q3 2025 report with net revenue of $38.2M and full-year guidance of $153.0–$163.0M to preliminary Q4 2025 net revenue of about $40.5M and $154.9M for full-year 2025. Acute Care products like ZYNRELEF and APONVIE were highlighted as key growth drivers, while APONVIE’s inclusion in PONV guidelines supported the franchise. Governance changes, including a new director, and prior earnings-date announcements set a pattern of regular communication that this new earnings-date notice continues.
Regulatory & Risk Context
The company has an effective Form S-3 shelf registration dated Sep 9, 2025 expiring on Sep 9, 2028, outlining a broad range of commercial, regulatory, financing, and litigation risks but with no disclosed usage to date.
Market Pulse Summary
This announcement schedules Heron’s fourth quarter and full-year 2025 results for February 26, 2026 at 8:30 a.m. ET, continuing a pattern of regular earnings communications. Investors may compare those results with prior disclosures, including preliminary 2025 net revenue of about $154.9M and product trends in ZYNRELEF and APONVIE. Key items to watch will be updated revenue, profitability metrics, and any revisions to guidance or commercialization plans across the portfolio.
AI-generated analysis. Not financial advice.
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
FAQ
When will Heron Therapeutics (HRTX) report Q4 and full year 2025 results?
How can investors access the Heron Therapeutics (HRTX) earnings call on February 26, 2026?
Will Heron Therapeutics (HRTX) provide a replay of the February 26, 2026 webcast?
What topics will Heron Therapeutics (HRTX) cover during the February 26, 2026 call?
What time should participants join the Heron (HRTX) conference call to avoid delays?
